Effect of srhCD40L on Proliferation and the Induction of Apoptosis of Human Breast Carcinoma Cell Lines
Cell Line . | Treatment . | CPM (±SD) . | NMP (U/mL) . |
---|---|---|---|
MDA-231 (CD40+) | — | 14,567 (216) | <2 |
srhCD40L (1 μg/mL) | 6,875 (158)† | 26* | |
srhCD40L (1 μg/mL) | 9,778 (364)* | 18* | |
Anti-fas (10 ng/mL) | 5,098 (206)† | 38* | |
T47D (CD40+) | — | 37,658 (1,897) | 8 |
srhCD40L (10 μg/mL) | 22,592 (2,025)* | 36* | |
srhCD40L (1 μg/mL) | 27,798 (2,046)* | 27* | |
Anti-fas (10 μg/mL) | 11,674 (1,923)† | 58* | |
MCF-7 (CD40−) | — | 19,867 (1,216) | 0 |
srhCD40L (10 μg/mL) | 18,976 (321) | 0 | |
srhCD40L (1 μg/mL) | 20,981 (1,786) | 0 | |
Anti-fas (10 μg/mL) | 7,930 (483)† | 37* |
Cell Line . | Treatment . | CPM (±SD) . | NMP (U/mL) . |
---|---|---|---|
MDA-231 (CD40+) | — | 14,567 (216) | <2 |
srhCD40L (1 μg/mL) | 6,875 (158)† | 26* | |
srhCD40L (1 μg/mL) | 9,778 (364)* | 18* | |
Anti-fas (10 ng/mL) | 5,098 (206)† | 38* | |
T47D (CD40+) | — | 37,658 (1,897) | 8 |
srhCD40L (10 μg/mL) | 22,592 (2,025)* | 36* | |
srhCD40L (1 μg/mL) | 27,798 (2,046)* | 27* | |
Anti-fas (10 μg/mL) | 11,674 (1,923)† | 58* | |
MCF-7 (CD40−) | — | 19,867 (1,216) | 0 |
srhCD40L (10 μg/mL) | 18,976 (321) | 0 | |
srhCD40L (1 μg/mL) | 20,981 (1,786) | 0 | |
Anti-fas (10 μg/mL) | 7,930 (483)† | 37* |